BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20161030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160109
DTSTAMP:20260729T213226
CREATED:20151218T112802Z
LAST-MODIFIED:20181103T080437Z
UID:11928-1452124800-1452297599@ces.b2sg.org
SUMMARY:USCAP 108th Annual Meeting: ASCP & ASIP Joint Meeting
DESCRIPTION:Current and Future Revolution in Pathology Practice: (Focus on) Immuno-oncology and Cancer Epigenetics \nASIP/ASCP will bring together 4 speakers from across two unique disciplines of pathology to discuss the practice\, science\, and challenges of immuno-oncology and cancer epigenetics intended to inform and education residents\, fellows\, and practicing pathologists.  The course will begin with a practical discussion of IO in current practice (Mamatha Chivukula\, Sutter Health\, CA) from the perspective of a community-based pathologist. This segment will review the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc.\, with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions. This will be followed up by a discussion of cutting-edge science in the IO space (Mike Milone\, UPenn) with emphasis on those technologies and tools that are likely to move into clinical space soon. This same approach to cancer epigenetics (David Williams\, UNC) will be revealed and discussed in the third presentation. Both of these cutting-edge talks will identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics.  To finish off\, a “future talk” focused on how cancer epigenetics will affect patient care and everyday diagnostics will be presented (Idriss M. Bennani-Baiti\, President\, Cancer Epigenetics Society\, Vienna\, Austria). This portion will assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care. \nCourse Learning Objectives\nUpon completion of this educational activity\, the learner will be able to: \n\nReview the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc. with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions\nIdentify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics\nAssess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care\n\n\nSESSION CHAIRS\n\n\nModerator \nDanny Milner\, MD\, MSc\, ASCP\n\n\n\n\n\nPRESENTATIONS\n\n\n1:30 PM\n1:35 PM\n\n\nIntroduction to the Session and Outline of the Symposium Objectives\n\n\nDanny Milner\, MD\, MSc\nASCP\n\n\n\n\n\n\n\n1:35 PM\n2:10 PM\n\n\n“Immunotherapy” From Bench to Community Practice- Are Pathologists Ready for the #gamechanger?\n\n\nMamatha Chivukula\, MD\, FASCP\nMills-Peninsula Hospital\, Sutter Health Affiliate\n\n\n\n\n\n\n\n2:10 PM\n2:45 PM\n\n\nCutting Edge Science in Immuno-Oncology: Where to next?\n\n\nMichael Milone\, MD\, Phd\nUniversity of Pennsylvania Perelman School of Medicine\n\n\n\n\n\n\n\n2:45 PM\n3:20 PM\n\n\nBreak\n\n\n\n\n\n\n3:20 PM\n3:55 PM\n\n\nFrom DNA Methylation to Chromatin Remodeling\, the Expanding Role of Epigenetic Changes in Cancer Biology\n\n\nDavid Williams\, MD\, PhD\nUniversity of North Carolina at Chapel Hill\n\n\n\n\n\n\n\n3:55 PM\n4:30 PM\n\n\nPractical Epigenetics: How Today’s Cancer Epigenetics Research Will Change the Field of Pathology Tomorrow\n\n\nIdriss Bennani-Baiti\, PhD\nChildren’s Cancer Research Institute Vienna\n\n\n\n\n\n\n\n4:30 PM\n5:00 PM\n\n\nPanel Discussion\n\n\nDanny Milner\, MD\, MSc
URL:https://ces.b2sg.org/event/ascp-asip-joint-meeting/
LOCATION:National Harbor\, Maryland\, Singapore
CATEGORIES:Meetings
END:VEVENT
END:VCALENDAR